TIMM17B

Across TCGA pan-cancer cohorts, TIMM17B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TIMM17B data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TIMM17B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TIMM17B expression acts as an unfavorable survival marker.

KIRC and SKCM are the cancer types where TIMM17B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.180	0.796	.001	30	view →
SKCM	OS	Median	All	0.145	0.781	<.001	13	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TIMM17B–KIRC (DFS)

Open the KIRC breakdown →